These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29902520)

  • 1. Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.
    Wen Z; Liang Y; Hao Y; Delavan B; Huang R; Mikailov M; Tong W; Li M; Liu Z
    Drug Discov Today; 2019 Jan; 24(1):9-15. PubMed ID: 29902520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Structure-Activity Relationship (QSAR) Model for the Severity Prediction of Drug-Induced Rhabdomyolysis by Using Random Forest.
    Zhou Y; Li S; Zhao Y; Guo M; Liu Y; Li M; Wen Z
    Chem Res Toxicol; 2021 Feb; 34(2):514-521. PubMed ID: 33393765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rest easy, statin users. Benefits dwarf risks for these cholesterol drugs.
    Comarow A
    US News World Rep; 2001 Sep; 131(8):45. PubMed ID: 11550394
    [No Abstract]   [Full Text] [Related]  

  • 4. In silico prediction of drug-induced rhabdomyolysis with machine-learning models and structural alerts.
    Cui X; Liu J; Zhang J; Wu Q; Li X
    J Appl Toxicol; 2019 Aug; 39(8):1224-1232. PubMed ID: 31006880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
.
    Hashiguchi M; Hakamata J; Shimizu M; Maruyama J; Shiga T; Mochizuki M
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):310-320. PubMed ID: 29701171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug-induced rhabdomyolysis].
    Chichmanian RM; Mignot G; Spreux A
    Ann Med Interne (Paris); 1991; 142(8):587-91. PubMed ID: 1807179
    [No Abstract]   [Full Text] [Related]  

  • 8. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A; Bansal V; Chugh A; Mookhtiar K
    Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
    Alsheikh-Ali AA; Ambrose MS; Kuvin JT; Karas RH
    Circulation; 2005 Jun; 111(23):3051-7. PubMed ID: 15911706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report.
    Rifkin SI
    Medscape J Med; 2008; 10(11):264. PubMed ID: 19099014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.
    Reis BY; Olson KL; Tian L; Bohn RL; Brownstein JS; Park PJ; Cziraky MJ; Wilson MD; Mandl KD
    Drug Saf; 2012 May; 35(5):395-406. PubMed ID: 22506565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton Pump Inhibitors and Risk of Rhabdomyolysis.
    Duncan SJ; Howden CW
    Drug Saf; 2017 Jan; 40(1):61-64. PubMed ID: 27838824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituting for cerivastatin (Baycol).
    Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
    Vrkić Kirhmajer M; Macolić Šarinić V; Šimičević L; Ladić I; Putarek K; Banfić L; Božina N
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):509-518. PubMed ID: 29734517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
    Piorkowski JD
    JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis.
    Gosho M
    Fundam Clin Pharmacol; 2019 Jun; 33(3):339-346. PubMed ID: 30575126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Adverse Drug Reaction Prediction with Deep Chemical Language Model for Drug Safety Evaluation.
    Lin J; He Y; Ru C; Long W; Li M; Wen Z
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects.
    Kontsioti E; Maskell S; Anderson I; Pirmohamed M
    Clin Pharmacol Ther; 2024 Jul; 116(1):165-176. PubMed ID: 38590106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin and the statin wars--the way to peace.
    Meyboom RH; Edwards IR
    Lancet; 2004 Dec 4-10; 364(9450):1997-9. PubMed ID: 15582043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.